JUPITER
Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin
Patient / Population Intervention / Exposure Comparison Outcome
In 17,802 adults with LDL < 130 mg/dL and hsCRP ≥ 2 mg/L, rosuvastatin reduced major vascular events versus placebo.
N
17,802
Design
Double-blind RCT, stopped early at median 1.9 yr
Endpoint
MI, stroke, hosp UA, revasc or CV death
Relevance
2
Result0.77 vs 1.36 per 100 pt-yr (HR 0.56).
Ridker PM, et al. N Engl J Med. 2008;359(21):2195-2207. 10.1056/NEJMoa0807646
Discussion & critique
Extended statin benefit to apparently 'normal-LDL' primary prevention with inflammatory risk. Early termination + commercial sponsorship drew criticism; reanalyses confirmed signal.